United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $21,707,270.53. The trade was a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Down 1.8%

Shares of UTHR stock opened at $522.83 on Friday. The company has a 50 day moving average price of $495.95 and a 200-day moving average price of $473.13. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $549.50. The firm has a market capitalization of $22.92 billion, a PE ratio of 18.74, a P/E/G ratio of 1.88 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the prior year, the firm earned $6.19 earnings per share. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. Analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on UTHR shares. Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Wells Fargo & Company upped their price objective on United Therapeutics from $466.00 to $486.00 and gave the company an “equal weight” rating in a research report on Monday, March 23rd. UBS Group increased their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, TD Cowen upped their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $549.91.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. lifted its holdings in United Therapeutics by 10.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 127 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of United Therapeutics by 13.5% in the fourth quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock worth $9,379,000 after purchasing an additional 2,289 shares in the last quarter. Rehmann Capital Advisory Group raised its position in shares of United Therapeutics by 9.8% during the 4th quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock valued at $1,767,000 after purchasing an additional 324 shares during the period. Tobam lifted its stake in shares of United Therapeutics by 28.9% during the 4th quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock valued at $4,803,000 after buying an additional 2,211 shares in the last quarter. Finally, Wick Capital Partners LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at $297,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.